Crescent appoints ex-Trinity chief Brendan Farrell CEO
This article was originally published in Clinica
Executive Summary
Irish osteoporosis detection specialist Crescent Diagnostics has appointed Brendan Farrell CEO. Mr Farrell most recently headed up EnBio, which specialises in surface modification technology for the medical and non-medical industries; before this, he was president and CEO of Irish diagnostics firm Trinity Biotech from 1994 until 2008. Dublin-based Crescent is developing a test for osteoporosis called BQT that analyses chemical bonds in a small toenail clipping, which has been shown to predict the future risk of hip fracture. The company is about to begin a Series B funding round through which it hopes to raise €5m ($6.6m) to accelerate the commercialisation of BQT. It is currently planning a pivotal study to support CE marking and US FDA approval. Mr Farrell replaces former Crescent CEO Ernest Poku, who left the company due to family commitments.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.